Invention Grant
- Patent Title: Phosphorylcholine in combination therapy with infliximab
-
Application No.: US15149969Application Date: 2016-05-09
-
Publication No.: US10669332B2Publication Date: 2020-06-02
- Inventor: Johan Frostegård
- Applicant: ATHERA BIOTECHNOLOGIES AB
- Applicant Address: SE Stockholm
- Assignee: ATHERA BIOTECHNOLOGIES AB
- Current Assignee: ATHERA BIOTECHNOLOGIES AB
- Current Assignee Address: SE Stockholm
- Agency: Stites & Harbison, PLLC
- Agent Stephen J. Weyer, Esq.
- Main IPC: C07K16/24
- IPC: C07K16/24 ; C07K14/525 ; C07K16/28 ; A61K35/28 ; A61K39/395 ; C07K16/18 ; A61K39/00

Abstract:
Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
Public/Granted literature
- US20180148502A9 Antibodies against phosphorylcholine in combination therapy with biologic agents Public/Granted day:2018-05-31
Information query